News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing: 73–81
Matches: 81
Sources here: 7
Companies here: 1

Search results Stored financial headlines Latest headline 09:11, 19 July 2026

Active search

81 matching headlines

Ticker or company: INSMMain company stories

Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

09:11 19 Jul 2026

Webull Earnings Main company 🇺🇸 United States

Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3

Insmed has reported positive 12-month open-label extension data for TPIP in pulmonary arterial hypertension, showing sustained improvements in clinical endpoints with no new safety signals. These results pave the way for a Phase 3 randomized, controlled trial, providing a new data point for investors …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

16:39 17 Jul 2026

Moomoo Guidance Main company 🇺🇸 United States

A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237

This article provides an overview of recent analyst ratings for Insmed (INSM.US), highlighting a consensus price target range of $161 to $237. It outlines the bullish sentiment surrounding the stock based on these expert evaluations. The information suggests a positive outlook for Insmed's potential …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

13:10 17 Jul 2026

BioSpace Regulatory and legal Main company 🇺🇸 United States

Insmed moves closer to $6B opportunity as PAH drug shows long-term durability

Insmed's investigational pulmonary arterial hypertension (PAH) drug, treprostinil palmitil inhalation powder (TPIP), demonstrated "impressive" long-term efficacy and biomarker improvements in an open-label extension study. Guggenheim Partners projects peak TPIP sales to exceed $6 billion across various indications, citing functional improvements and significant reductions in …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

13:10 17 Jul 2026

Investing.com Analyst action Main company 🇺🇸 United States

Insmed stock price target maintained at $200 by Stifel on trial data

Stifel reiterated a Buy rating and a $200 price target for Insmed (NASDAQ:INSM) after the company released 12-month open-label extension data from its Phase 2b trial for TPIP, a pulmonary arterial hypertension treatment candidate. The data showed continued clinical benefit and reinforces the drug's …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

09:11 17 Jul 2026

Moomoo Market update Main company 🇺🇸 United States

Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients

Insmed announced that data from their Phase 1 TREMOLOTM and Phase 2 BEATTM studies indicate that treprostinil showed sustained benefits for pulmonary arterial hypertension (PAH) patients. The data suggests that the drug could improve pulmonary vascular hemodynamics, functional capacity, and clinical outcomes. Insmed is …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

21:27 16 Jul 2026

Seeking Alpha Earnings Main company 🇺🇸 United States

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients - Slideshow (NASDAQ:INSM)

Insmed Incorporated (INSM) has released a slide deck detailing the 12-month results from its ongoing open-label extension study of TPIP in patients with Pulmonary Arterial Hypertension (PAH). This information was published in conjunction with an event. The study's findings are presented in a slideshow …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

20:10 16 Jul 2026

Insmed Incorporated Investor Relations Earnings Main company 🇺🇸 United States

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Insmed announced positive 12-month data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The data showed sustained improvement in efficacy measures, including a reduction in mortality risk, and TPIP was well-tolerated with no new safety signals. …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

12:42 16 Jul 2026

Investing.com Earnings Main company 🇺🇸 United States

Insmed reports 12-month data for PAH treatment candidate

Insmed (NASDAQ:INSM) announced positive 12-month open-label extension study data for its treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). Patients showed significant improvement in six-minute walk distance and decreased NT-proBNP concentration. Despite trading above its fair value according to InvestingPro, …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

11:42 16 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Insmed reports positive 12-month OLE results for TPIP showing sustained 6MWD, ~60% NT-proBNP drop

Insmed announced positive 12-month Open-Label Extension (OLE) results for TPIP, demonstrating sustained efficacy and good tolerability. The study showed a mean 6MWD improvement in both continued and placebo-crossed groups, aligning by Month 12, along with a significant ~60% drop in NT-proBNP levels and improved …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

Search the Newsreel

81 matching headlines

Matching headlines

Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3

A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237

Insmed moves closer to $6B opportunity as PAH drug shows long-term durability

Insmed stock price target maintained at $200 by Stifel on trial data

Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients - Slideshow (NASDAQ:INSM)

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Insmed reports 12-month data for PAH treatment candidate

Insmed reports positive 12-month OLE results for TPIP showing sustained 6MWD, ~60% NT-proBNP drop

Search the Newsreel

Send a message

Evidence context